A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• The polyamine transport system (PTS) is crucial for cellular growth and is often upregulated in cancer.
• F14512, a novel spermine epipodophyllotoxin conjugate, targets cancer cells via the PTS and is in clinical development for acute myeloid leukemia (AML).

Purpose of the Study:

• To investigate the antiproliferative effects of F14512 in leukemia cell lines.
• To establish a correlation between PTS activity and F14512 efficacy.
• To adapt a novel fluorescent marker (F96982) for clinical assessment of PTS activity in AML patients.

Main Methods:

• In vitro antiproliferative assays of F14512 against 13 leukemia cell lines.
• Quantification of PTS activity using the novel fluorescent probe F96982.
• Adaptation of the F96982 labeling protocol for clinical samples (blood, bone marrow) with CD45 gating.

Main Results:

• F14512 demonstrated significant antiproliferative effects across tested leukemia cell lines.
• A statistically significant correlation was observed between F14512's antiproliferative activity and the level of PTS activity.
• PTS activity varied significantly between AML cells and normal lymphocytes in patient samples.

Conclusions:

• The novel fluorescent probe F96982 effectively identifies PTS activity in AML cells.
• PTS activity levels can predict patient response to F14512 therapy.
• This approach offers a new strategy for selecting patients likely to benefit from F14512 treatment in AML.